TROPiCS-02: Sacituzumab Govitecan in HR+/HER2- Metastatic or Locally Recurrent Breast Cancer

Opinion
Video

Experts on breast cancer offer comprehensive insights on findings from the TROPiCS-02 study investigating sacituzumab govitecan in patients with HR+/HER2- metastatic or locally recurrent inoperable breast cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following question:

      • Please comment on the patient population, study design and key objectives from the phase 3 TROPiCS-02 study of sacituzumab govitecan in patients with HR+/HER2- metastatic or locally recurrent inoperable breast cancer.
      Recent Videos
      Targeting ESR1 Mutations in Breast Cancer With Novel Therapies
      Targeting ESR1 Mutations in Breast Cancer With Novel Therapies
      2 experts in this video
      Considerations for Treatment Approaches in Intermediate-Stage HCC
      2 experts in this video
      Navigating the Evolving First-Line Treatment Regimens in Intermediate-Stage HCC
      Shortened Radiation Trial Advances Breast Cancer Treatment
      Shortened Radiation Trial Advances Breast Cancer Treatment
      Understanding the Significance of ESR1 Mutations in Breast Cancer
      Understanding the Significance of ESR1 Mutations in Breast Cancer
      2 experts in this video
      When to Move Beyond TACE: The Expanding Role of Systemic Therapy in Intermediate-Stage HCC
      2 experts in this video
      Current Treatment Practices in Embolization-Eligible HCC
      42nd Annual Miami Breast Cancer Conference: The Show and After Show
      42nd Annual Miami Breast Cancer Conference: The Show and After Show
      Considering Elacestrant in ESR1+ Breast Cancer After CDK4/6 Inhibition
      Considering Elacestrant in ESR1+ Breast Cancer After CDK4/6 Inhibition
      Sequencing and AEs Guide Next Steps for Dato-DXd in Breast Cancer
      Sequencing and AEs Guide Next Steps for Dato-DXd in Breast Cancer
      Related Content
      FDA Updates Decision on ProSense Cryoablation for Early-Stage Breast Cancer

      FDA Updates Decision on ProSense Cryoablation for Early-Stage Breast Cancer

      Jordyn Sava
      March 20th 2025
      Article

      The FDA has extended its review of the ProSense cryoablation system for early-stage breast cancer, with a decision expected after the first quarter of 2025.

      Read More

      Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

      Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

      Jordyn Sava;Aditya Bardia, MD, MPH
      February 6th 2025
      Podcast

      In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

      Listen

      Advancing Treatments for ET and CDK4/6 Resistance in HR+ Breast Cancer

      Advancing Treatments for ET and CDK4/6 Resistance in HR+ Breast Cancer

      Silas Inman
      March 10th 2025
      Article

      New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

      Read More

      Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

      Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

      Jordyn Sava;Sanjay K. Juneja, MD
      January 15th 2025
      Podcast

      In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

      Listen

      HR+/MP-H2 Breast Cancers Resemble Triple-Negative, Guiding New Therapies

      HR+/MP-H2 Breast Cancers Resemble Triple-Negative, Guiding New Therapies

      Jordyn Sava
      March 3rd 2025
      Article

      Alejandro Rios Hoyo discussed findings on a subset of hormone receptor–positive, HER2-negative breast cancers classified as MP-H2.

      Read More

      Camizestrant Plus CDK4/6 Inhibitors Shows PFS Benefit in HR+/HER2- Breast Cancer

      Camizestrant Plus CDK4/6 Inhibitors Shows PFS Benefit in HR+/HER2- Breast Cancer

      Jordyn Sava
      February 26th 2025
      Article

      Camizestrant combined with CDK4/6 inhibitors improved progression-free survival in HR+/HER2- advanced breast cancer with ESR1 mutations in the SERENA-6 trial.

      Read More